|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Among these, we discovered that DR4 was not modified by <i>O</i>-GlcNAc in most of the TRAIL-resistant cancer cells and DLD-1<sup>PER</sup> cells.
|
30987996 |
2019 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Natural products have shown excellent potential to restore apoptosis in TRAIL-resistant cancer cell lines and in mice xenografted with TRAIL-resistant cancer cells.
|
31022877 |
2019 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Understanding this mechanism's driving forces may facilitate the induction of cell death in TRAIL-resistant cancer cells.
|
29661248 |
2018 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrated that activation of PPARγ mediated by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux and also suggest that troglitazone may be a combination therapeutic target with TRAIL protein in TRAIL-resistant cancer cells.
|
28460464 |
2017 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data demonstrate that inhibition of Akt/mTOR by glipizide sensitizes TRAIL-induced tumor cell death through activating autophagy flux and also suggest that glipizide may be a combination therapeutic target with TRAIL protein in TRAIL-resistant cancer cells.
|
29245957 |
2017 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we show that TRAIL-triggered cytokine secretion from TRAIL-resistant cancer cells is FADD dependent and identify the TRAIL-induced secretome to drive monocyte polarization to myeloid-derived suppressor cells (MDSCs) and M2-like macrophages.
|
28212753 |
2017 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MSCT-EVs induced pronounced apoptosis in TRAIL-resistant cancer cells and this effect could be further enhanced using a CDK9 inhibitor.
|
28326166 |
2017 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Among the 18 TRAIL-resistant cancer cell lines used, 15 cell lines become sensitive or highly sensitive to ART, and two out of three glioma cell lines exhibit high resistance to ART treatment due to very low levels of procaspase-8.
|
27210546 |
2016 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, low-dose okadaic acid treatment sensitized TRAIL-resistant cancer cells to TRAIL, suggesting that PP2A inhibitors could be used as an enhancer of apoptosis induced by TRAIL or TRAIL-like agents.
|
24296757 |
2014 |
|
Refractory cancer
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In our present study, we found that carnitine, a metabolite that transfers long-chain fatty acids into mitochondria for beta-oxidation and modulates protein kinase C activity, sensitizes TRAIL-resistant cancer cells to TRAIL.
|
23068102 |
2012 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TRAIL is an apoptotic inducer, but it can nonetheless trigger non-apoptotic signals favoring tumorigenesis in apoptosis-resistant cancer cells.
|
22576662 |
2012 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, UA also sensitized TRAIL-resistant cancer cells to the cytokine.
|
21156789 |
2011 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Besides an enhanced selectivity, these TRAIL-DR4 agonists show superior affinity to DR4, and a high apoptosis-inducing activity against several TRAIL-sensitive and -resistant cancer cell lines in vitro.
|
21368856 |
2010 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HW1 treatment as a single agent induces autophagic cell death in a variety of both TRAIL-sensitive and TRAIL-resistant cancer cells, but exhibits much less cytotoxicity on normal cells.
|
17671202 |
2007 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Upon infection, DR4 expression was slightly increased in cancer cell lines, and cell death was observed in TRAIL-resistant cancer cell lines but not in normal human cells when DR4 infection was combined with TRAIL treatment.
|
16502485 |
2006 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, downregulating PKCK2 activity is required for TRAIL-mediated apoptosis to occur in TRAIL-resistant cancer cells.
|
16193064 |
2005 |
|
Refractory cancer
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Ionizing radiation may enhance the apoptosis inducing potential of TRAIL in sensitive cells, and sensitize TRAIL-resistant cancer cells.
|
15067334 |
2004 |